Core Viewpoint - Covalon Technologies Ltd. has granted a total of 97.674 Deferred Share Units (DSUs) to four non-employee directors as part of their annual directors' fees for fiscal year 2026, opting for DSUs instead of cash [1][2]. Group 1: Deferred Share Units (DSUs) - The DSUs were granted under the Amended and Restated Omnibus Long-Term Incentive Plan, effective March 25, 2026 [2]. - The DSUs will vest 12 months from the date of grant, with a deemed value calculated at $1.72 per share, based on the last closing price prior to the grant [2]. Group 2: Company Overview - Covalon is an advanced medical technologies company focused on improving patient outcomes through innovative medical products and technologies, including advanced wound care and surgical consumables [4]. - The company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF) [4].

Core Viewpoint - Canadian Goldfields Discovery Corp. has announced the appointment of Mr. Chris Kinver to its Board of Directors, enhancing its leadership team in anticipation of a fully funded exploration program for the Miminiska Gold Project in Ontario [1][7]. Company Appointments - Mr. Chris Kinver, a Mining Engineer with over 20 years of experience, has been appointed to the Board. He has held senior management roles in various mining operations and has a strong background in underground mining and project management [1][2]. - The Company has also established a new Advisory Board, appointing James Burns, Mike Hofer, and Mick Carew, each bringing extensive experience in business leadership, environmental management, and geology, respectively [3][4][5][6]. Compensation and Stock Options - The Company has adopted a Security Based Compensation Plan (SBC Plan) aimed at attracting and retaining qualified personnel, aligning their interests with shareholders, and encouraging participation in the Company's growth. The maximum number of Awards under the SBC Plan is fixed at 9,380,000 [7][8]. - The Board has approved the grant of 9,350,000 stock options at an exercise price of $0.45 per share, with a five-year term, and plans to grant 7,925,000 Restricted Share Units (RSUs) subject to shareholder approval [9]. Investor Relations - The Company has engaged Mr. Conrad Orzel for investor relations services from March 11, 2026, to September 11, 2026, for a fee of $3,000 per month and 50,000 stock options at $0.45 per share [10][11].

Group 1 - Rise Gold Corp. has granted a total of 1,445,469 stock options to directors, officers, and consultants under its Long Term Incentive Plan, with an exercise price of US$0.25 (CAD$0.35) per share until October 30, 2030 [1] - The Company has also granted 1,365,854 deferred share units (DSUs) to certain directors and officers, with each DSU entitling the holder to receive one Common Share upon cessation of being an Eligible Person [2] - Rise Gold is an exploration-stage mining company incorporated in Nevada, USA, with its principal asset being the historic Idaho-Maryland Gold Mine located in Nevada County, California [3]

Core Viewpoint - Marvel Biosciences Corp. has awarded 142,987 deferred share units (DSUs) to two directors as a form of compensation instead of cash payment, with the DSUs set to vest on July 31, 2026 [1][2]. Group 1: Company Overview - Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company [3]. - The company is developing MB-204, a novel fluorinated derivative of the anti-Parkinson's drug Istradefylline, which is the only clinically approved adenosine A2a antagonist [3]. - There is growing scientific evidence suggesting that drugs blocking the adenosine A2a receptor, like MB-204, may be effective in treating various neurological diseases, including autism, depression, and Alzheimer's Disease [3]. - The company is also exploring the potential of MB-204 in addressing neurodevelopmental disorders such as Rett Syndrome and Fragile X Syndrome to broaden its therapeutic applications [3]. Group 2: Financial Details - The deemed value of the awarded DSUs is calculated at $0.16 per share based on the volume-weighted average price (VWAP) of the company's common shares on the TSX Venture Exchange as of July 31, 2025 [2]. - Vested DSUs will be settled upon the directors' separation from the company and will expire 365 days after such separation [2].